Neil Alexander Hoye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil Alexander Hoye has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Shaojie Chen
Department of Cardiology, Elisabethinen University Teaching Hospital Linz, Linz, Austria
4 shared publicationsGerard T. Wilkins
Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, Otago, New Zealand
3 shared publicationsLuis Marcelo Rodrigues Paz
Interventional Cardiology Section, Department of Cardiology, Hospital e Clínica São Gonçalo, São Gonçalo, RJ, Brazil
3 shared publications- Luke C. Wilson
Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
3 shared publications - Márcio Galindo Kiuchi
School of Medicine-Royal Perth Hospital Unit, University of Western Australia, Australia (M.G.K.).
3 shared publications David L. Jardine
Department of Medicine University of Otago Christchurch Otago New Zealand
2 shared publications
Latest Publications
- 21 November 2018
- Published by Wiley in Seminars in Dialysis
- Vol. 32 (3) , 255-265
Sympathetic overactivity in dialysis patients—Underappreciated and clinically consequential
Cardiovascular morbidity and mortality remain frustratingly common in dialysis patients. A dearth of established evidence‐based treatment calls for alternative therapeutic avenues to be embraced. Sympathetic hyperactivity, predominantly due to afferent nerve signaling from the diseased native kidneys, has been established to be prognostic in the dialysis population for over 15 years. Despite this, tangible therapeutic interventions have, to date, been unsuccessful and the outlook for patients remains poor. This narrative review summarizes established experimental and clinical data, highlighting recent developments, and proposes why interventions to ameliorate sympathetic hyperactivity may well be beneficial for this high‐risk population.
- 21 November 2018
- Published by Wiley in Seminars in Dialysis
- Vol. 32 (3) , 255-265
Sympathetic overactivity in dialysis patients—Underappreciated and clinically consequential
Cardiovascular morbidity and mortality remain frustratingly common in dialysis patients. A dearth of established evidence‐based treatment calls for alternative therapeutic avenues to be embraced. Sympathetic hyperactivity, predominantly due to afferent nerve signaling from the diseased native kidneys, has been established to be prognostic in the dialysis population for over 15 years. Despite this, tangible therapeutic interventions have, to date, been unsuccessful and the outlook for patients remains poor. This narrative review summarizes established experimental and clinical data, highlighting recent developments, and proposes why interventions to ameliorate sympathetic hyperactivity may well be beneficial for this high‐risk population.
- 20 December 2017
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 51 (1) , 51-59
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker
Atrial fibrillation (AF) commonly occurs in chronic kidney disease (CKD), occasioning adverse outcomes. Merging pulmonary vein isolation (PVI) and renal sympathetic denervation (RSD) may decrease the recurrence of AF in subjects with CKD and uncontrolled hypertension. We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity. We aimed to evaluate the impact of RSD or spironolactone 50 mg/day associated with PVI in reducing systolic blood pressure (BP), AF recurrence, and AF burden in patients with a history of paroxysmal AF and mild CKD.
- 20 December 2017
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 51 (1) , 51-59
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker
Atrial fibrillation (AF) commonly occurs in chronic kidney disease (CKD), occasioning adverse outcomes. Merging pulmonary vein isolation (PVI) and renal sympathetic denervation (RSD) may decrease the recurrence of AF in subjects with CKD and uncontrolled hypertension. We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity. We aimed to evaluate the impact of RSD or spironolactone 50 mg/day associated with PVI in reducing systolic blood pressure (BP), AF recurrence, and AF burden in patients with a history of paroxysmal AF and mild CKD.
- 18 December 2017
- Published by Springer Nature in Herz
- Vol. 44 (5) , 412-418
Renal denervation for mild–moderate treatment-resistant hypertension
Renal denervation (RDN) has been proposed as a novel antihypertensive intervention for treating resistant hypertension. It remains to be investigated which patient groups can potentially benefit from RDN. The present study aimed to evaluate the efficacy and safety of RDN in patients with mild–moderate resistant hypertension, i. e., systolic office blood pressure (BP) of 140–160 mm Hg despite treatment with three antihypertensive drugs including one diuretic, or mean systolic BP by ambulatory BP monitoring (ABPM) of 135–150 mm Hg.
- 18 December 2017
- Published by Springer Nature in Herz
- Vol. 44 (5) , 412-418
Renal denervation for mild–moderate treatment-resistant hypertension
Renal denervation (RDN) has been proposed as a novel antihypertensive intervention for treating resistant hypertension. It remains to be investigated which patient groups can potentially benefit from RDN. The present study aimed to evaluate the efficacy and safety of RDN in patients with mild–moderate resistant hypertension, i. e., systolic office blood pressure (BP) of 140–160 mm Hg despite treatment with three antihypertensive drugs including one diuretic, or mean systolic BP by ambulatory BP monitoring (ABPM) of 135–150 mm Hg.
- Open Access
- 30 September 2017
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 36 (3) , 264-273
The effects of different physical activities on atrial fibrillation in patients with hypertension and chronic kidney disease
Márcio Galindo Kiuchi, Shaojie Chen, Neil Alexander Hoye. Kidney Res Clin Pract 2017;36:264-73. https://doi.org/10.23876/j.krcp.2017.36.3.264
- 30 September 2017
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 36 (3) , 264-273
Open AccessThe effects of different physical activities on atrial fibrillation in patients with hypertension and chronic kidney disease
Márcio Galindo Kiuchi, Shaojie Chen, Neil Alexander Hoye. Kidney Res Clin Pract 2017;36:264-73. https://doi.org/10.23876/j.krcp.2017.36.3.264
- Open Access
- 1 September 2017
- Published by Elsevier in Kidney International Reports
- Vol. 2 (5) , 856-865
Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection—A Proof-of-Concept Study
- 1 September 2017
- Published by Elsevier in Kidney International Reports
- Vol. 2 (5) , 856-865
Open AccessEndovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection—A Proof-of-Concept Study
- Open Access
- 5 June 2017
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 15, 6-9
Influence of vitamin D on the percentage time of cardiac resynchronization in patients with heart failure, premature ventricular complexes, and chronic kidney disease
- 5 June 2017
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 15, 6-9
Open AccessInfluence of vitamin D on the percentage time of cardiac resynchronization in patients with heart failure, premature ventricular complexes, and chronic kidney disease
- Open Access
- 18 April 2017
- Published by Wiley in Physiological Reports
- Vol. 5 (8) , e13248
Resting heart rate variability and exercise capacity in Type 1 diabetes
People with type 1 diabetes (T1D) have lower exercise capacity (V̇O2max) than their age‐matched nondiabetic counterparts (CON), which might be related to cardiac autonomic dysfunction. We examined whether Heart Rate Variability (HRV; indicator of cardiac autonomic modulation) was associated with exercise capacity in those with and without T1D. Twenty‐three participants with uncomplicated T1D and 17 matched CON were recruited. Heart rate (HR; ECG), blood pressure (BP; finger photo‐plethysmography), and respiratory rate (respiratory belt) were measured during baseline, paced‐breathing and clinical autonomic reflex tests (CARTs); deep breathing, lying‐to‐stand, and Valsalva maneuver. Baseline and paced‐breathing ECG were analyzed for HRV (frequency‐domain). Exercise capacity was determined during an incremental cycle ergometer test while V̇O2, 12‐lead ECG, and BP were measured. In uncomplicated T1D, resting HR was elevated and resting HRV metrics were reduced, indicative of altered cardiac parasympathetic modulation; this was generally undetected by the CARTs. However, BP and plasma catecholamines were not different between groups. In T1D, V̇O2max tended to be lower (P = 0.07) and HR reserve was lower (P < 0.01). Resting Total Power (TP) had stronger positive associations with V̇O2max (R 2 ≥ 0.3) than all other traditional indicators such as age, resting HR, and self‐reported exercise (R 2 = 0.042–0.3) in both T1D and CON. Alterations in cardiac autonomic modulation are an early manifestation of uncomplicated T1D. Total Power was associated with reduced exercise capacity regardless of group, and these associations were generally stronger than traditional indicators.
- 18 April 2017
- Published by Wiley in Physiological Reports
- Vol. 5 (8) , e13248
Open AccessResting heart rate variability and exercise capacity in Type 1 diabetes
People with type 1 diabetes (T1D) have lower exercise capacity (V̇O2max) than their age‐matched nondiabetic counterparts (CON), which might be related to cardiac autonomic dysfunction. We examined whether Heart Rate Variability (HRV; indicator of cardiac autonomic modulation) was associated with exercise capacity in those with and without T1D. Twenty‐three participants with uncomplicated T1D and 17 matched CON were recruited. Heart rate (HR; ECG), blood pressure (BP; finger photo‐plethysmography), and respiratory rate (respiratory belt) were measured during baseline, paced‐breathing and clinical autonomic reflex tests (CARTs); deep breathing, lying‐to‐stand, and Valsalva maneuver. Baseline and paced‐breathing ECG were analyzed for HRV (frequency‐domain). Exercise capacity was determined during an incremental cycle ergometer test while V̇O2, 12‐lead ECG, and BP were measured. In uncomplicated T1D, resting HR was elevated and resting HRV metrics were reduced, indicative of altered cardiac parasympathetic modulation; this was generally undetected by the CARTs. However, BP and plasma catecholamines were not different between groups. In T1D, V̇O2max tended to be lower (P = 0.07) and HR reserve was lower (P < 0.01). Resting Total Power (TP) had stronger positive associations with V̇O2max (R 2 ≥ 0.3) than all other traditional indicators such as age, resting HR, and self‐reported exercise (R 2 = 0.042–0.3) in both T1D and CON. Alterations in cardiac autonomic modulation are an early manifestation of uncomplicated T1D. Total Power was associated with reduced exercise capacity regardless of group, and these associations were generally stronger than traditional indicators.
- Open Access
- 1 March 2017
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 14, 29-32
Effects of renal sympathetic denervation on heart rate variability in uncontrolled hypertensive patients with chronic kidney disease
- 1 March 2017
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 14, 29-32
Open AccessEffects of renal sympathetic denervation on heart rate variability in uncontrolled hypertensive patients with chronic kidney disease
- Open Access
- 1 March 2017
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 14, 53-58
Influence of vitamin D levels on the treatment of premature ventricular complexes in patients with chronic kidney disease
- 1 March 2017
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 14, 53-58
Open AccessInfluence of vitamin D levels on the treatment of premature ventricular complexes in patients with chronic kidney disease
- Open Access
- 5 February 2017
- Published by International Cardiovascular Forum Journal in Journal of Advanced Therapies and Medical Innovation Sciences
- Vol. 2
Pharmacological Monotherapy versus Renal Artery Denervation in Controlled Hypertensive Patients
Aim: The aim of this prospective observational non-inferiority study was to compare the capacity for control of essential hypertension between renal sympathetic denervation (RSD) and either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).Methods and results: Seventy-four previously controlled essential hypertensive patients on ACEI/ARB monotherapy were evaluated; eleven patients agreed to proceed with RSD and had their antihypertensive agent withdrawn on the day of the procedure. During the six months of follow-up, there was no significant change in mean 24-hour ambulatory blood pressure measurements (ABPM) from baseline to three and sixmonths in the ACEI/ARB group (118±8/80±3 vs. 116±8/79±3 and 115±8/79±4 mmHg, respectively). No change was also observed in the RSD group (117±8/81±2 vs. 115±6/80±2 and 114±7/79±3 mmHg, respectively). There were no differences between groups at interval time points. There were also no changes in renal function or echocardiographic parameters, during follow-up.Conclusions: For the first time, this study reports possible non-inferiority of RSD when compared to ACEI or ARB monotherapy in the control of essential hypertension. A randomized trial with appropriate concealment of treatment, more patients and an extended follow-up period is needed to evaluate the potential benefits of RSD in comparison to ACEI/ARB use in patients with controlled hypertension.
- 5 February 2017
- Published by International Cardiovascular Forum Journal in Journal of Advanced Therapies and Medical Innovation Sciences
- Vol. 2
Open AccessPharmacological Monotherapy versus Renal Artery Denervation in Controlled Hypertensive Patients
Aim: The aim of this prospective observational non-inferiority study was to compare the capacity for control of essential hypertension between renal sympathetic denervation (RSD) and either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).Methods and results: Seventy-four previously controlled essential hypertensive patients on ACEI/ARB monotherapy were evaluated; eleven patients agreed to proceed with RSD and had their antihypertensive agent withdrawn on the day of the procedure. During the six months of follow-up, there was no significant change in mean 24-hour ambulatory blood pressure measurements (ABPM) from baseline to three and sixmonths in the ACEI/ARB group (118±8/80±3 vs. 116±8/79±3 and 115±8/79±4 mmHg, respectively). No change was also observed in the RSD group (117±8/81±2 vs. 115±6/80±2 and 114±7/79±3 mmHg, respectively). There were no differences between groups at interval time points. There were also no changes in renal function or echocardiographic parameters, during follow-up.Conclusions: For the first time, this study reports possible non-inferiority of RSD when compared to ACEI or ARB monotherapy in the control of essential hypertension. A randomized trial with appropriate concealment of treatment, more patients and an extended follow-up period is needed to evaluate the potential benefits of RSD in comparison to ACEI/ARB use in patients with controlled hypertension.